Study of HSK40118 for advanced lung cancer with EGFR mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have advanced non-small cell lung cancer (NSCLC) with an EGFR mutation that has spread or cannot be removed by surgery.
- You have already been treated with at least one EGFR-targeted therapy (like erlotinib, afatinib, or osimertinib) and, for some parts of the study, you must have tried a third-generation EGFR-targeted therapy (like osimertinib).
- You are physically active enough to care for yourself (ECOG score 0 or 1) and expected to live at least 3 months.
- You have not taken a fourth-generation EGFR-targeted therapy before.
- You do not have any major health problems that would interfere with the study, such as uncontrolled heart disease, active infections, or bleeding issues.
- You agree to provide a blood or tumor sample if possible, and women who can have children must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new drug (RC108) combined with furmonertinib, with or without an immune drug (toripalimab), in people with EGFR-mutated lung cancer that has gotten worse after prior EGFR treatment. It aims to see how safe the treatment is and whether it can shrink tumors or help control the disease.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
This Phase 1 study tests HS-20117 to see if it is safe and how well it works in people with advanced solid tumors. You may qualify if your cancer has progressed after standard treatments (or you can’t tolerate them) and you can provide new or stored tumor tissue for testing.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation or MET-positive) and has worsened after prior treatment. It aims to see if the combination is safe and effective.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.